{"filings":[{"id":2520440,"accession_number":"0001193125-26-371265","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2026-08-27T20:06:14+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 revenue down 23% to $42.4M; FY revenue down 20% to $182.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $42.4M (-23.1% YoY); Americas -24.8%, APAC/Europe -16.9%.","Q4 EPS $0.10 GAAP, $0.11 adjusted; FY EPS $0.40, adj $0.56.","FY revenue $182.6M (-20.1%); gross margin 77.6% on MindBody GLP-1 obsolescence.","Adj EBITDA Q4 $2.7M vs $4.8M; FY $13.7M vs $22.1M.","No FY27 guidance due to CEO transition; repurchased 336k shares ~$2M, $58.5M left."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":182586000.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2024202,"accession_number":"0001193125-26-330531","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2026-08-03T20:05:17+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeVantage adopts 2026 New Employee LTIP, reserving 1.5M shares for new-hire equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2026 New Employee Long-Term Incentive Plan on July 31, 2026.","Plan reserves 1,500,000 shares of common stock for issuance to new employees as inducement grants.","Awards limited to new hires or rehires after bona fide non-employment; no incentive stock options allowed.","Plan adopted without stockholder approval under Nasdaq Rule 5635(c)(4).","Plan substantially similar to 2017 LTIP except no ISOs and only for eligible new employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99189,"accession_number":"0001193125-26-208934","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q3 revenue drops 25%; EPS falls to $0.11; guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $43.7M, down 25.2% YoY; Americas down 28.9%, Asia/Pacific & Europe down 7.7%.","Net income $1.4M ($0.11 diluted EPS) vs $3.5M ($0.26) prior year; adjusted EPS $0.12.","Adjusted EBITDA $3.2M, halved from $6.4M; operating income $1.7M vs $4.1M.","Dividend raised 11.1% to $0.05/share, payable June 15, 2026 to holders of record June 1.","Fiscal 2026 guidance expected near lower end of prior range; no specific numbers provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":140209000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99188,"accession_number":"0001193125-26-159324","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeVantage names Terrence Moorehead CEO; current CEO Steve Fife retiring Apr 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Fife retires as President and CEO effective April 30, 2026; transition agreement with advisory through Sept 11, 2026.","Terrence Moorehead appointed President, CEO and Board member effective August 5, 2026; formerly CEO of Nature's Sunshine Products 2018-2025.","Michael Beindorff appointed Interim CEO from May 1 to Aug 4, 2026; paid $45,833/month under consulting agreement.","Moorehead compensation: $850k base salary; annual cash bonus target up to 100%; RSUs of $2M (3-yr vest) + $800k prorated; PSUs of $3.5M + $1.2M (revenue/EBITDA targets).","Transition benefits for Fife: medical premiums up to 18 months, prorated FY2026 bonus, continued RSU/PSU vesting through transition term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115057,"accession_number":"0001628280-26-005431","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"LifeVantage Q2 revenue drops 27.8% to $48.9M; CEO Fife to retire in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.9M, down 27.8% YoY; Americas revenue fell 32.6%.","GAAP EPS $0.02 vs $0.19; adjusted EPS $0.15 vs $0.22; adjusted EBITDA $3.9M vs $6.5M.","Inventory obsolescence charge of $2.4M for MindBody GLP-1 System weighed on gross margin.","New $60M share repurchase authorization approved; quarterly dividend $0.045/share.","CEO Steve Fife to retire in April 2026; board conducting executive search."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":96493000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131447,"accession_number":"0001628280-25-055939","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeVantage CMO and CIO resign, effective Dec 12 and Dec 24, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Julie Boyster resigns effective December 12, 2025 to pursue other opportunities.","CIO Todd Thompson resigns effective December 24, 2025 to pursue other opportunities.","No replacements have been announced for either officer role.","Departures were disclosed in an 8-K filed December 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131446,"accession_number":"0001628280-25-051641","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage FY2026 annual meeting results: all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; Beindorff, Greer, Lewis received >1.9M against votes and 1.87M broker non-votes.","Advisory say-on-pay approved with 7.42M for vs 246k against (broker non-votes 1.87M).","Ratification of Deloitte as auditor passed with 9.54M for, 31k against.","Amendment to 2017 Long-Term Incentive Plan approved: 5.38M for, 2.31M against, 1.87M broker non-votes.","Turnout: 9.57M shares voted (75.4% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131445,"accession_number":"0001628280-25-048801","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q1 FY2026 revenue $47.6M (+0.7%), EPS $0.17 vs $0.14 a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $2.2M ($0.17 diluted EPS); adjusted EPS $0.18 vs $0.15.","Adjusted EBITDA $3.9M, down from $4.4M a year earlier.","Americas revenue +0.8%; Asia/Pacific & Europe revenue +0.4% (constant currency -1.4%).","Declared $0.045/share cash dividend payable Dec 15, 2025 to holders of record Dec 1, 2025.","Reaffirmed FY2026 guidance: revenue $225-240M, adj. EBITDA $23-26M, adj. EPS $1.00-1.15."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":47561000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148028,"accession_number":"0000849146-25-000069","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 revenue $55.1M (+12.6% YoY); full-year EPS $0.75 vs $0.23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $55.1M (+12.6%); net income $0.15 diluted EPS (adjusted $0.17).","FY25 revenue $228.5M (+14.2%); net income $0.75 diluted EPS vs $0.23; adjusted EPS $0.82.","FY25 adjusted EBITDA $22.1M (+30.3% YoY); Q4 flat at $4.8M.","FY2026 guidance: revenue $225-240M, adjusted EBITDA $23-26M, adjusted EPS $1.00-1.15.","Declared dividend $0.045/share payable Sept 16, 2025; repurchased 0.3M shares for $3.1M in FY25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166768,"accession_number":"0000849146-25-000041","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q3 revenue $58.4M (+21% YoY); EPS $0.26 vs $0.13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $3.5M ($0.26 diluted EPS) vs $1.7M ($0.13) a year ago; adjusted EPS also $0.26 vs $0.21.","Americas revenue rose 29.5%; Asia/Pacific & Europe fell 7.2% (down 4.7% constant currency).","Gross margin improved 210 bps to 81.0%; adjusted EBITDA $6.4M vs $5.1M.","FY2025 guidance: revenue $228-235M, adjusted EBITDA $21-24M, adjusted EPS $0.72-0.88; quarterly dividend $0.045."],"consensus_eps_estimate":0.1887,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":173416000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184182,"accession_number":"0000849146-25-000015","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q2 revenue up 31% to $67.8M; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $67.8M (+31.3% YoY); Americas +46.3%, APAC/Europe -15.5%.","Net income $0.19 diluted EPS vs loss $0.05; adjusted EPS $0.22 vs $0.10.","Adjusted EBITDA $6.5M vs $3.1M; operating income $3.4M vs loss $1.3M.","FY2025 guidance raised: revenue $235-245M, adj EBITDA $21-24M, adj EPS $0.72-0.88.","Declares $0.04/share dividend payable March 17, 2025; record March 3."],"consensus_eps_estimate":0.1581,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":114976000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200765,"accession_number":"0000849146-24-000146","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"LifeVantage eliminates Series A Preferred Stock after Rights Agreement expired","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Rights Agreement expired Aug 28, 2024; stock purchase rights terminated.","Certificate of Elimination filed Nov 18, 2024 with Delaware Secretary of State.","No shares of Series A Preferred Stock were issued or outstanding at filing.","Shares returned to authorized but undesignated preferred stock pool.","No impact on common stock rights or company operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200764,"accession_number":"0000849146-24-000142","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage annual meeting results: all eight directors elected, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected; votes ranged from 5.59M to 6.19M for.","Say-on-pay approved: 4.56M for, 1.61M against, 30k abstain.","Ratification of Deloitte as auditor approved with 8.7M for, 81k against.","Shareholders set say-on-pay frequency to every year (5.84M for every year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200763,"accession_number":"0000849146-24-000122","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q1 revenue falls 8.1% to $47.2M; net income rises to $0.14 diluted EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.14 diluted EPS vs $0.05 a year ago; adjusted EPS $0.15 vs $0.13.","Americas revenue down 4.2%; Asia/Pacific & Europe down 19.7% (18.7% constant currency).","Adjusted EBITDA rose 11% to $4.4M from $4.0M; margin improved 160 bps.","FY2025 guidance reaffirmed: revenue $200M-$210M, adj. EBITDA $18M-$21M, adj. EPS $0.70-$0.80.","Declared $0.04 dividend payable Dec 16, record Dec 2; repurchased 0.1M shares for $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":47214000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216781,"accession_number":"0000849146-24-000074","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 rev down 9.8% to $48.9M; FY adj EPS $0.59; FY25 guidance $200-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.10; adjusted EPS $0.14; revenue down 9.8% YoY to $48.9M.","FY2024 revenue $200.2M (-6.2%); adj EBITDA $17.0M (+44.7%); GAAP EPS $0.23 vs $0.20.","Declared $0.04 dividend payable Sep 17, record Sep 9; cash $16.9M, no debt.","FY2025 guidance: rev $200-210M, adj EBITDA $18-21M, adj EPS $0.70-0.80.","Americas rev -4.1%; Asia/Pacific & Europe -25.2% in Q4, impacted by forex."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":200164000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216780,"accession_number":"0000849146-24-000064","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Erin Brockovich resigns from LifeVantage board; Rajendran Anbalagan appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Brockovich resigned from LifeVantage board effective Aug 26, 2024; not due to any disagreement.","Rajendran Anbalagan appointed to board effective immediately; will serve on Nominating and Corporate Governance Committee.","Anbalagan brings digital/technology expertise; chosen to enhance customer experience and growth strategy.","He will receive initial restricted stock award of $105,000 prorated and standard non-employee director compensation.","Company entered indemnification agreement with Anbalagan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236490,"accession_number":"0000849146-24-000048","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q3 revenue falls 10.2% to $48.2M; guidance cut; adjusted EBITDA up 55%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.2M, down 10.2% YoY; Americas -5.9%, Asia/Pacific & Europe -22.4% (constant currency -16.1%).","GAAP EPS $0.13, adjusted EPS $0.21 vs $0.08 a year ago; adjusted EBITDA $5.1M, up 54.7%.","Fiscal 2024 revenue guidance lowered to $202-205M from $207-213M; adjusted EBITDA guidance unchanged at $16-18M.","Declared $0.04/share cash dividend payable June 14, 2024 to holders of record May 31, 2024.","Repurchased 0.3M shares for $1.9M in Q3; $22.3M remaining under buyback program; cash $17.4M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":151233000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236489,"accession_number":"0000849146-24-000039","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"LifeVantage enters $5M revolving credit facility with Bank of America, matures 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving line of credit up to $5,000,000 with Bank of America; interest at Term SOFR + 2.00% (floor 0.00%).","Facility matures April 12, 2027; monthly interest payments starting May 31, 2024; principal due at maturity.","Obligations secured by substantially all assets of LifeVantage and guaranteed by subsidiary Lifeline Nutraceuticals Corporation.","Includes up to $1,000,000 sublimit for stand-by letters of credit; 2.00% p.a. fee on undrawn amounts.","New facility replaces prior revolving credit agreement with Zions Bancorporation, which was discharged concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254129,"accession_number":"0000849146-24-000021","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"LifeVantage appoints Dayton Judd to board under cooperation agreement with activist investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Dayton Judd to Board; Board size increased by one seat.","Cooperation Agreement with Radoff-Sudbury Group (owns ~12.6% of LFVN) resolves books-and-records demand.","Standstill and voting commitments; Judd also on Audit and Nominating Committees.","Management reaffirms LV360 strategy targeting double-digit Adjusted EBITDA margins.","No financial terms disclosed; agreement ends before FY2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254128,"accession_number":"0000849146-24-000017","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q2 revenue down 3.8% to $51.6M; adjusted EBITDA up 289%; lowers FY revenue guidance, raises EPS guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.6M (-3.8% YoY); Americas -1.6%, Asia/Pacific & Europe -10.0% (-8.0% constant currency).","Net loss $0.7M ($0.05 loss per share) vs $1.1M loss; adjusted EPS $0.10 vs -$0.07.","Adjusted EBITDA $3.1M (+289%); margin improved 450 bps to 6%.","FY2024 revenue guidance cut to $207-213M from $216-226M; adjusted EPS raised to $0.57-0.67 from $0.52-0.62.","Declares $0.035/share dividend payable March 15, 2024; repurchased 0.4M shares for $2.7M in H1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":102988000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271597,"accession_number":"0000849146-23-000208","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K/A","filed_at":"2023-11-13T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"LifeVantage shareholders re-elect all seven incumbent directors, approve stockholder rights plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final certified results confirm all 7 incumbent directors re-elected; each received majority support.","Stockholder rights plan ratified with 4,651,264 for vs 4,120,670 against.","Say-on-pay passed with 5,937,422 for, 2,871,303 against.","Turnout of 72.85% of outstanding shares; proxy contest by Radoff/Sudbury defeated.","All proposals approved including amendment to 2017 Long-Term Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271599,"accession_number":"0000849146-23-000206","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage shareholders elect company's director slate, reject dissident nominees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven company-nominated directors elected; dissident candidates Bradley Radoff (3.1M for vs 6.1M withhold), Dayton Judd, and Michael Lohner defeated.","Director Garry Mauro won by narrow margin (4.61M for, 4.56M withhold).","Advisory say-on-pay passed with 5.94M for vs 2.87M against.","2017 LTIP amendment and stockholder rights plan ratified (5.89M for and 4.65M for, respectively).","All results preliminary, subject to certification by inspector of election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271598,"accession_number":"0000849146-23-000205","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q1 FY24 revenue $51.4M (-0.8% YoY); adj. EBITDA +41%, adj. EPS $0.13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.4M, down 0.8% YoY (ex-FX -0.2%). Americas +5.9%, US +6.5%; Asia/Pacific & Europe -16.6% (-14.6% constant currency).","GAAP EPS $0.05 flat YoY; adjusted EPS $0.13 vs $0.06. Adjusted EBITDA $4.0M, up 41.4% from $2.8M.","Total active accounts 137k, down 10.5% YoY (Americas -7.5%, APAC/EU -17.0%). Cash from operations $4.8M vs -$1.3M; no debt.","Dividend $0.035/share declared, payable Dec 15, record Dec 1. FY24 guidance: rev $216M-$226M, adj. EBITDA $16M-$18M, adj. EPS $0.52-$0.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":51364000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288465,"accession_number":"0000849146-23-000114","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"LifeVantage adopts limited duration stockholder rights plan expiring Aug 2024, with 12% trigger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One right per common share outstanding as of Sept 11, 2023 record date; exercise price $20 per right.","Rights become exercisable only if a person/group acquires 12% (20% for passive investors) without Board approval.","Upon trigger, each right (except acquirer's) allows purchase of common stock worth 2x the exercise price.","Board may redeem rights at $0.01 each before trigger; plan submitted to stockholder ratification at annual meeting.","Rights expire on August 28, 2024; limited duration and no dead-hand provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288464,"accession_number":"0000849146-23-000103","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 revenue up 6.4% to $54.2M; declares special $0.40 dividend; FY2024 EPS guide $0.52-0.62","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.15 vs loss $0.11 YoY; adjusted EPS $0.17 vs $0.01; revenue $54.2M (+6.4% YoY).","Americas revenue +17.9% (U.S. +18.6%); APAC/Europe -16.0%; total active accounts fell 8.3% to 143K.","Declared special cash dividend of $0.40/share plus regular $0.035/share, payable Sep 22, 2023.","FY2024 guidance: revenue $216-226M, adjusted EBITDA $16-18M, adjusted EPS $0.52-0.62 (28% tax rate).","Strong balance sheet: $21.6M cash, no debt; FY2023 operating cash flow $6.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":213398000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288463,"accession_number":"0000849146-23-000076","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LifeVantage confirms Bradley L. Radoff plans to nominate three directors for 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bradley L. Radoff notified LifeVantage of intent to nominate three candidates to the Board at fiscal 2024 annual meeting.","Board will review nominees and present recommendations in definitive proxy statement to be filed with SEC.","Stockholders encouraged to read proxy statement when available; no action required now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308980,"accession_number":"0000849146-23-000060","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LifeVantage extends stock repurchase program to Dec 31, 2026; authorizes 10b5-1 plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board extended stock repurchase program through December 31, 2026.","Authorized a pre-arranged 10b5-1 trading plan for limited share repurchases.","Repurchases under 10b5-1 plan subject to SEC rules, price, volume, and timing constraints.","CEO Steve Fife cited confidence in business trajectory and LV360 strategic transformation.","Company maintains balanced capital allocation: growth investments, quarterly dividends, and buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308979,"accession_number":"0000849146-23-000052","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q3 revenue up 7.5% to $53.7M; guides FY23 rev $209-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.7M (+7.5% YoY; +10.4% constant currency). Americas +18.2%, APAC/Europe -14.2%.","GAAP EPS $0.08 vs $0.09 YoY; adjusted EPS $0.08 vs $0.12; adjusted EBITDA $3.3M vs $3.4M.","Active accounts 149k, down 5.1% YoY; Americas flat, APAC/Europe -16.3%.","Dividend raised 16.7% to $0.035/share, payable June 15, 2023 to holders of record June 1.","FY2023 guidance: rev $209-212M, adjusted EBITDA $11-13M, adjusted EPS $0.20-0.26."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":159177000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308978,"accession_number":"0000849146-23-000043","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"LifeVantage appoints Deloitte & Touche as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee engaged Deloitte & Touche as new independent registered public accounting firm effective April 13, 2023.","No prior consultations with Deloitte regarding accounting principles, audit opinions, or reportable events.","No disagreements with prior auditor reported for fiscal years 2021 and 2022 or subsequent interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327747,"accession_number":"0000849146-23-000026","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeVantage COO Matt Cooley resigns, effective April 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Matt Cooley voluntarily resigns; last day of employment is April 4, 2023.","Resignation notice received by Company on March 20, 2023; no successor has been named.","Departure is described as voluntary, with no cause or dispute indicated in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327746,"accession_number":"0000849146-23-000020","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"LifeVantage auditor WSRP declines reappointment for FY2023; no disagreements cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WSRP notified LifeVantage on Feb 15, 2023 it will not stand for reappointment for FY ending June 30, 2023.","No disagreements or reportable events occurred in fiscal 2022, 2021, or the subsequent interim period.","WSRP may continue services through Q1 FY2024 if a successor is not appointed in time.","Company expects to engage a replacement auditor in a timely fashion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327745,"accession_number":"0000849146-23-000016","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q2 revenue $53.7M (+2.8% YoY); net loss $0.08 EPS; guides FY rev $202-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.7M, up 2.8% YoY (7.4% constant currency); Americas up 14.4%, Asia/Pac & Europe down 20.2%.","Net loss $1.1M ($0.08 per diluted share) vs net income $0.01 per share a year ago.","Adjusted EBITDA $0.8M vs $1.9M prior year; active accounts fell 8.6% to 149,000.","Declares $0.03 per share cash dividend, payable March 15, 2023 to holders of record March 1.","FY2023 guidance: revenue $202-212M, adj. EBITDA $11-13M, adj. EPS $0.22-0.28."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":105436000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327744,"accession_number":"0000849146-23-000012","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LifeVantage adopts new distributor compensation plan effective March 1, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New plan initially applies to US, Australia, New Zealand, and Japan markets.","Plan will roll out to other markets over the following 12 months.","Compensation plan change is effective March 1, 2023.","No financial or performance details disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345436,"accession_number":"0000849146-22-000099","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K/A","filed_at":"2022-11-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage shareholders elect all seven directors, approve say-on-pay, auditor, and LTIP amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Beindorff, Brockovich, Fife, Greer, Latham, Lewis, Mauro.","Advisory say-on-pay approved with 3.39M for, 0.66M against.","Ratification of WSRP LLC as auditor for FY2023 passed with 7.94M for.","Amendment to 2017 Long-Term Incentive Plan approved with 3.47M for.","Broker non-votes of 4.30M on director elections and proposals 2 and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345438,"accession_number":"0000849146-22-000097","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-11-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage shareholders elect all six director nominees at FY2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Voter turnout 66.63% (8,369,050 of 13,235,944 shares represented).","All six director nominees elected; Darwin K. Lewis received highest votes for with 3,796,342.","Advisory 'say-on-pay' approved: 3,388,050 for, 659,309 against.","Ratification of WSRP as auditor: 7,940,835 for, 103,034 against.","Amendment to 2017 Long-Term Incentive Plan approved: 3,471,779 for, 575,564 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345437,"accession_number":"0000849146-22-000078","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q1 revenue $51.8M (-2.7% YoY); adj. EPS $0.06 vs $0.23; dividend $0.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.8M, down 2.7% YoY; constant-currency revenue up 2.3%.","Net income $0.6M ($0.05 diluted EPS) vs $3.3M ($0.25) a year ago.","Adjusted EBITDA $2.8M vs $5.8M; active accounts declined 6.7% to 153,000.","Declared $0.03/share cash dividend payable Dec 15, 2022 to holders of record Dec 1.","FY2023 guidance: revenue $200M-$212M, adj. EBITDA $12M-$14M, adj. EPS $0.27-$0.39."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":51774000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361885,"accession_number":"0000849146-22-000059","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-08-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 revenue down 7% to $50.9M; GAAP EPS loss $0.11 vs $0.35 profit YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $50.9M (-7% YoY); Americas down 10.5%, Asia/Pacific & Europe up 0.7% (up 12.8% ex-FX).","GAAP diluted EPS -$0.11 vs $0.35; adjusted diluted EPS $0.01 vs $0.31.","Full-year revenue $206.4M (-6.3%); GAAP EPS $0.24 vs $0.90; adjusted EPS $0.41 vs $1.00.","Board declares $0.03/share quarterly dividend payable Sept 15 to holders of record Sept 2.","FY2023 guidance: revenue $200-$212M; adjusted EBITDA $12-$14M; adj. EPS $0.27-$0.39."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":206360000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381336,"accession_number":"0000849146-22-000028","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q3 revenue down 3%; cuts FY2022 guidance; initiates $0.03 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $50.0M, down 3% YoY (less than 1% ex-FX); EPS diluted $0.09, adjusted $0.12.","Adjusted EBITDA $3.4M, down 29.2% YoY; active accounts fell 6.5% to 157,000.","Initiates quarterly dividend of $0.03/share payable May 31, 2022 to holders of record May 17.","Reduces FY2022 guidance: revenue $204-207M (from $212-220M); adjusted EPS $0.52-0.56 (from $0.67-0.71).","Cash $17.8M, no debt; repurchased 326k shares in Q3 for $1.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":155418000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399324,"accession_number":"0000849146-22-000020","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeVantage Chief Sales Officer Justin Rose departs effective March 7, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Rose's employment as Chief Sales Officer ended March 7, 2022.","No reason for departure was disclosed in the filing.","No replacement or interim appointment has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399323,"accession_number":"0000849146-22-000015","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeVantage appoints Cindy Latham to Board of Directors effective Feb 17, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cindy Latham appointed to the Board and Compensation Committee, term expires at fiscal 2023 annual meeting.","Latham is a senior marketing executive with 30+ years in direct selling, including global marketing and R&D.","Initial restricted stock award of $75,000 prorated for months until fiscal 2023 annual meeting; vests in one year.","Non-employee director monthly cash retainer of $5,000; indemnification agreement entered into with Latham."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399322,"accession_number":"0000849146-22-000010","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q2 revenue $52.2M, down 11.6% YoY; cuts FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $52.2M, down 11.6% YoY; EPS $0.01 diluted; adjusted EPS $0.05.","Active accounts fell 6.3% to 163,000; Americas down 11%, APAC up 6.4%.","FY2022 revenue guidance reduced to $212-220M (prev $225-235M); adj. EBITDA $18-20M (prev $22-24M).","Repurchased ~0.5M shares for $3.2M in Q2; balance sheet strong with $20.2M cash, no debt.","Appointed new CMO and CDO to senior leadership team."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":105414000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418315,"accession_number":"0000849146-21-000109","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeVantage annual meeting elects all six director nominees; say-on-pay and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with >4.5M votes for each; broker non-votes ~3.73M.","Advisory say-on-pay approved with 4,367,044 for, 348,791 against, 66,757 abstain.","Ratification of WSRP LLC as auditor for FY2022 passed with 8,194,485 for, 231,175 against.","Turnout was 64.3% of 13,235,944 outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418314,"accession_number":"0000849146-21-000106","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q1 FY2022 revenue $53.2M (-2.9% YoY); adjusted EPS $0.23 (-8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $53.2M, down 2.9% YoY; Americas -5.8%, Asia/Pacific & Europe +3.9%.","GAAP diluted EPS $0.25 (+47.1%); adjusted diluted EPS $0.23 (-8.0%); adjusted EBITDA $5.8M (-13.7%).","Total active accounts fell 4.7% to 164k; Americas -9.4% partly offset by Asia/Pacific & Europe +8.9%.","Repurchased ~0.5M shares for $3.5M; cash $19.9M, no debt.","FY2022 guidance reaffirmed: rev $225-235M, adj. EBITDA $22-24M, adj. EPS $0.83-0.87."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":53224000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418313,"accession_number":"0000849146-21-000099","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LifeVantage appoints Carl Aure as CFO; Steven Fife remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl Aure appointed CFO effective Oct 25, 2021, replacing Steven Fife who remains CEO.","Base salary $350,000; target bonus 50% of base under C-Suite bonus plan.","Equity awards: 35,000 restricted shares (3-yr vest), 22,500 time-based RSUs, and 22,500 performance-based RSUs.","Aure previously CAO at New Age, with 15+ years in direct selling and prior experience at KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435876,"accession_number":"0000849146-21-000079","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2021-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LifeVantage Q4 revenue $54.8M (-7.7% YoY), adj EPS $0.31 (+10.7% YoY); FY22 guidance $225-235M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $54.8M, down 7.7% YoY; Americas -9.6%, Asia/Pacific & Europe -3.3%.","GAAP diluted EPS $0.35, up 34.6% YoY; adjusted EPS $0.31, up 10.7% YoY.","Active accounts 170,000, down 5% YoY but up 1.2% sequentially; distributors -13.7% YoY, customers +0.9%.","Full year revenue $220.2M (-5.5% YoY); adjusted EBITDA $24.8M (+3.7% YoY).","FY22 guidance: revenue $225-235M, adj EBITDA $22-24M, adj EPS $0.83-0.87."],"consensus_eps_estimate":null,"consensus_eps_actual":0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":220181000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435875,"accession_number":"0000849146-21-000068","cik":849146,"company_name":"Lifevantage Corp","ticker":"LFVN","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Vinayak Hegde will not stand for re-election at LifeVantage fiscal 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vinayak Hegde informed LifeVantage on Aug 12, 2021, he will not stand for re-election.","Annual meeting expected on or about Nov 11, 2021; departure not due to disagreements.","Hegde served as a Board member; no replacement named in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":101557363.08080809,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}